1 Department of Paediatrics and Child Health, Obafemi Awolowo University, Ile Ife, Osun State, Nigeria.
2 Department of Paediatrics, Obafemi Awolowo University Teaching Hospitals Complex, Ile Ife, Osun State, Nigeria.
Received: July 17, 2017
Accepted: September 19, 2017
Mediterr J Hematol Infect Dis 2017, 9(1): e2017063 DOI 10.4084/MJHID.2017.063
This article is available on PDF format at:
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
haemoglobin (HbF) is a major modifying factor influencing sickle cell
disease (SCD) severity. Despite this, HbF estimation is not routinely
done in Nigeria. The relationship between HbF and SCD severity among
affected children is also poorly studied.
The presence of high foetal haemoglobin had been documented to ameliorate the disease severity in the western world where children with SCD are routinely given hydroxyurea in order to induce the production of foetal haemoglobin and reduce frequent crises. However, children in Nigeria and most other African countries still suffer devastating complications such as stroke, priapism, acute chest syndrome and deep sited infections like meningitis and cerebral abscess. Foetal haemoglobin level had been reported to be higher among Jamaican and Asian children with the consequent milder course of the disease. In Nigeria, there is a paucity of data on the influence of foetal haemoglobin levels on disease severity among children with SCA. Hence, this study aimed at determining the relationship between foetal haemoglobin level and disease severity among children with SCA in steady state.
A data proforma was used to obtain the socio-demographic characteristics such as age, sex and socio-economic class of participants as described by Oyedeji based on rank assessment of parental occupation and the level of education. The clinical severity of SCD was determined based on the number of admissions, blood transfusions and
significant painful crises (pain episode that requires a hospital visit and the use of analgesic) in the preceding 12 months and other complications present as described by Adegoke et al. Patients with a score of less than 8 were classified as having mild disease, 8 to 17 as moderate disease and greater than 17 as a severe disease from a total obtainable score of 34.
Venous blood sample was obtained and analysed for the complete blood count using ABX Micros ES 60® automated haemoanalyser and foetal haemoglobin levels using an automated BIO-RAD® D10 high-performance liquid chromatography (HPLC) machine at the Haematology Laboratory of the National Sickle Cell Foundation Lagos, Nigeria. Using the cut-off values of 10%, patients with HbF levels <10% were categorised as having low HbF while those with values ≥10% were categorised as having high HbF levels.
Statistical analysis. Data were analysed using the statistical package for the social sciences (SPSS) software for windows version 17.0. Means (± standard deviation, SD), median, proportions and percentages were determined as applicable. The means and standard deviations (±SD) were calculated for continuous variables while proportions and percentages were calculated for categorical variables. Categorical variables were compared with chi-squared or Fisher’s exact tests while continuous data were compared with independent sample t-test, Mann-Whitney U test or Analysis of variance (ANOVA) as indicated. The degree of correlation of continuous data was determined by Pearson’s correlation analysis. Logistic regression analysis was done to examine the independent effect of foetal haemoglobin on SCD severity. Statistical significance was established when the p-value was less than 0.05.
|Table 1. Socio-demographic characteristics of the 105 subjects.|
Clinical burden of the disease. Table 2 shows that 89 (84.8%) experienced at least one episode of pain and 33 (31.4%) had more than three significant painful episodes requiring hospital visit and the use of analgesia in the 12 months preceding the study. Sixteen (15.2%) did not experience any significant painful episode in the year preceding the study. Fifty-one (48.6%) children required hospitalisation including two (1.9%) that required more than three admissions in the 12 months preceding the study. Twenty-one (20%) children were transfused at least once in the year prior to recruitment. Also, 45 (42.9%) subjects had a history of dactylitis. The mean age at which they had the first dactylitis was 1.2±1.0 years, ranging from three months to four years.
|Table 2. Frequency of pain episodes, SCD-related hospitalisation and transfusion among the subjects in the 12 months preceding the study.|
Sickle cell disease severity. The sickle cell disease severity score ranged from 0-14 with a mean score of 6.0±3.2. Using a score of 0-7 for mild disease, 8-17 for moderate and >17 for severe disease, 73 (69.5%) had mild disease, 32 (30.5%) had moderate disease while none had severe disease.
The most common complication of SCA among the subjects was acute chest syndrome, seen in 19 (18.1%) of the children followed by osteomyelitis in 14 (13.3%). Other complications included stroke in 3 (2.9%), avascular necrosis of head of femur, chronic leg ulcers and priapism, 2 (1.9%) each.
Foetal haemoglobin levels in the subjects. The mean HbF level was 9.9 ± 6.0% with a range of 0.8 - 27.6%. Sixty-six (62.9%) had low HbF levels of less than 10% while 39 (37.1%) had high HbF value ≥10%. None had a 0% value.
Relationship between socio-demographic characteristics and foetal haemoglobin. Table 3 shows that male children had significantly lower mean haemoglobin F levels than females, 8.0±5.6% vs 12.2±5.8% (p<0.001). Also, significantly higher proportion of males (78.0% vs. 22.0% of females) had HbF levels <10%; χ2=13.168; p<0.001. Additionally, the mean HbF across the age groups decreased with age and this was statistically significant (χ2=3.851, p=0.024). The 39 subjects who had high HbF were significantly younger than those with low HbF (6.3±4.1 years vs. 7.8±3.3 years, t=2.150, p=0.034). Also, 19 (54.3%) of the 35 children who were 1-5 years compared with 20 (28.6%) of the 70 who were >5 years (i.e. age groups 6-10 years and 11-15 years) had high HbF levels, χ2=6.608, p=0.010. There was a significant inverse correlation between HbF levels and age for both sexes, as shown in figure 1, r=- 0.3, p=0.004 for females, and r=- 0.3 , p=0.006 for males.
On the other hand, the mean HbF levels were not statistically different in the socioeconomic classes (p=0.877) and were not influenced by the frequency of pain crisis, blood transfusion and hospital admissions, p=0.147; 0.808; and 0.347 respectively.
|Table 3. Relationship between foetal haemoglobin levels, socio-demographic and clinical burden of children with sickle cell anaemia.|
|Figure 1. Scatter plots showing the correlation between foetal haemoglobin levels and age of the patients in both sexes.|
Relationship between socio-demographic characteristics and SCD severity. Disease severity worsens with age. Higher proportion of those >5 years, i.e. 27 (38.6%) of the 70 as against 5 (14.3%) of the 35 aged 1-5 years had moderate SCD severity. Those older than 5 years were 3.8 times more likely to have moderate disease severity than those aged 1-5 years, odd ratio =3.8, 95% confidence interval =1.3-10.9, p=0.011. Also, more males, 39.0% (23/59) compared to 19.6% females (9/46) had moderate disease, OR=0.4, 95% CI=0.2-0.9, p=0.032. Socioeconomic class did not significantly influence SCD severity. The proportions of children with mild disease who came from high social class (66.6%) and middle/low social classes (69.8%) were similar, OR=0.9, 95% CI=0.2-3.7, p=1.000.
Relationship between foetal haemoglobin and disease severity. Those with moderate disease had significantly lower mean foetal haemoglobin levels than those with mild disease (7.7±5.6% vs 10.8±6.0% respectively; p=0.013). Also, significantly higher proportion of subjects with moderate disease (78.1%) as against those with mild disease (56.2%) had HbF levels <10% (χ2=4.596, p=0.032). On the other hand, more of the children with mild SCD severity (43.8%) than those with moderate disease (21.9%) had high levels of HbF (HbF ≥10%).Sickle cell disease severity score had significant inverse correlation with HbF levels (r=- 0.3, p=0.002).
Relationship between foetal haemoglobin and clinical characteristics. Table 4 shows that the mean foetal haemoglobin level was significantly lower in children who had a history of acute chest syndrome than those without this complication, (t=-3.243, p=0.002). Similarly, children with a history of stroke had significantly lower HbF than those without the history of stroke (t=- 4.296, p=0.010). There was, however, no difference in the mean foetal haemoglobin levels of those with a history of osteomyelitis, septic arthritis, leg ulcer, priapism, avascular necrosis and dactylitis when compared to those without these complications. From table 5, higher proportion of children with low HbF had previous ACS (χ2=5.033, p=0.025).
|Table 4. Relationship between the mean foetal haemoglobin level and complications of sickle cell anaemia in the subjects.|
|Table 5. Distribution of complications of sickle cell anaemia by the level of foetal haemoglobin.|
Multivariate logistic regression analysis. Logistic regression analysis was done to examine the independent effect of foetal haemoglobin on SCD severity. In the regression model, disease severity (dichotomised as mild or moderate) was taken as the outcome/dependent variable, and age group (1-5 vs>5 years), gender (male vs female), socio-economic class (high vs middle/low) and foetal haemoglobin (high vs low HbF) were all taken as the predictive/independent factors. None of these factors [age group, OR 0.3, 95% CI 0.1-1.0, p=0.050; gender, OR 1.9, 95% CI 0.7-5.0, p=0.198; social class, OR 0.9, 95% CI 0.2-4.4, p=0.947 and foetal haemoglobin, OR 1.8, 95% CI 0.6–5.2, p=0.262] was found to be a significant independent predictor of SCD severity.
The clinical burden of SCA in our unit reflects the high burden of this disease in most parts of developing countries. In this study, about 85 percent of the children had experienced at least one significant pain episode necessitating hospital visit and use of analgesia; while about 20 percent were transfused and 50 percent were admitted for SCD-related morbidities in the twelve months preceding the study. These findings agree with the report by Brown et al among SCA children at the University College Hospital, Ibadan. It was also found in this study that about one-third of the subjects had more than three episodes of vaso-occlusive crisis and indeed this was responsible for most of the hospital admissions among them. This situation is consistent with the trend in some countries such as Britain and Saudi Arabia.[13,14] Although the frequency of pain and admissions have been reduced significantly in developed nations following the widespread use of hydroxyurea, this drug is not readily available, accessible and affordable in Nigerian and other sub-Saharan African countries where the principal precipitants of vaso-occlusive crises such as malaria and sepsis are still prevalent.
The mean HbF level of the children with SCA in this study is higher than what has been reported previously in most Nigerian studies. Isah in Sokoto found mean HbF level of 2.99±5.16 percent as against 9.9±6.0 percent in the present study. Also, the mean HbF level in this study is higher than 7.2±5.0 percent reported by Tshilolo in Congo. This discrepancy may be due to the difference in the method of foetal haemoglobin estimation. The Betke method of alkali denaturation was used by Isah while HPLC which is a more sensitive method was used in the present study. Age difference might also account for the differences in the haemoglobin F level. For instance, relatively lower values were obtained in previous studies of adult sickle cell patients by Omoti in Benin (2.17±1.81 percent), Durosinmi in Ife (4.26±4.33 percent), Olaniyi in Ibadan (5.16±4.04 percent) and Uko in Calabar (3.05±1.61 percent).[18-21]
A study among children with SCA in Uganda reported a mean HbF level of 9.0±5.58 percent despite using alkali denaturation test. A higher value (12.2±7.1 percent) was also reported in India by Rao et al. The reason for the differences may be due to the effect of various factors that influence foetal haemoglobin production in SCA individuals. One of the factors is beta gene haplotype of the disease. The Senegal, Saudi and Indian haplotypes are generally associated with higher levels of foetal haemoglobin and milder disease course while the Benin haplotype which is found commonly in our environment and the Cameroon haplotype are intermediate and of varying clinical manifestation. However, the Bantu haplotype is associated with severe disease and low foetal haemoglobin production. Another major factor that affects foetal haemoglobin level includes hydroxyurea, a ribonucleotide reductase inhibitor. The exact mechanism of how hydroxyurea increases HbF levels is not clear. It is frequently used in the western world in the management of children with sickle cell disease. Unfortunately, most children in Nigeria and other resource-poor countries in sub-Saharan Africa with the largest burden of the disease are not benefitting due to non-availability and/or unaffordability of the drug.
A recent in-vitro study highlighted a beneficial effect of Tropical almond (Terminalia cattapa) in inducing HbF levels in erythroid progenitor cells. Possibly, a large-scale study and clinical trials on in-vivo use of this agent in children with SCA living in resource-poor countries may determine if it could be of comparative clinical utility. Currently, a Nigerian child who is using a 500mg capsule of hydroxyurea daily would spend close to 10 US dollars per month on HU therapy alone, in a country where more than 70 percent of the population is poor.
This present study found about two-thirds of our children with SCA (62.9 percent) had low foetal haemoglobin levels, and this was demonstrated in the pattern of the burden and complications seen in this study. We also observed that a significantly higher proportion of children with moderate disease severity compared to those with mild disease severity (78.1% vs 56.2%) had low levels of HbF. On the other hand, more of the children with mild SCD severity than those with moderate disease had high levels of HbF. A similar finding was reported by Mpalampa et al. among children with SCA in Uganda. Also, females in the present study had significantly higher HbF compared to males. This datum is similar to that found by Falusi et al. in a study of adult patients with SCA as well as in other studies by Mouele in Congo and Alsultan in Saudi Arabia. Olaniyi et al. in Ibadan, Nigeria found no difference in the HbF levels in both adult males and females with SCA. Falusi et al. attributed the finding to hormonal factor at puberty. However, in children, the exact reason for the higher levels of haemoglobin F among girls may not be explained by hormonal changes alone. The exact reason remains unclear, perhaps the X-linked co-dominant gene controlling the production of HbF may lead to a double dose of the gene as is the case for females unlike males, resulting in higher elaboration of the gene products, hence, higher HbF levels in females than males. The mean HbF was also found to be inversely related to age and significantly reduces with increasing age. This datum is similar to the finding of Adekile et al. among SCA individuals in Kuwait. It may be due to the relatively higher amount of F cells in the younger age group as observed by Akinsheye et al.
We found that the mean foetal haemoglobin levels were significantly lower in children with moderate disease severity than those with mild disease and also in those who had a history of acute chest syndrome and stroke than those without these complications. Although there are no local data to corroborate or refute this observation, our findings are similar to the report by Mpalampa from Uganda. Increased polymerisation of the sickle cell haemoglobin in the presence of lower foetal haemoglobin may account for these unfavourable events among children with SCA. We did not find any relationship between foetal haemoglobin levels and previous history of priapism, osteomyelitis, septic arthritis and leg ulcer. Although a higher level of foetal haemoglobin has been found to be associated with fewer complications, the non-significant relationship between foetal haemoglobin and these other complications in this present study may be due to the fewer number of study participants with these complications.
Our study has some limitations. First, it is a cross-sectional study from a single centre. This type of study design is subject to recall, investigator and survival biases. In particular, information on the lifetime incidence of complications and frequency of significant pain episodes may have been subject to recall bias, despite the review of relevant medical charts in addition to clinical histories to obtain that information. Secondly, the relatively small number of patients studied could also affect generalisability of our findings. Future studies should be multi-centred, longitudinal in design and involve a larger population.
It is concluded that foetal haemoglobin level has a significant inverse relationship with disease burden and severity among children with sickle cell anaemia. Advanced age and male gender were also significantly related to low foetal haemoglobin levels in these children. Therefore, it is recommended that facilities for early and regular quantification of foetal haemoglobin be made available, and access to HbF inducing agents, specifically hydroxyurea encouragedin order to reduce the morbidity and mortality among these children.
AcknowledgementWe appreciate the cooperation of the parents and children who participated in this study.
- Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;86(6):480-7. https://doi.org/10.2471/BLT.06.036673 PMid:18568278 PMCid:PMC2647473
- Sickle-cell anaemia. Agenda item 11.4. In: 59th World Health Assembly; 2006; Geneva: World Health Organization. http://www.who.int/iris/handle/10665/20890
- Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: A multicentre, randomised, controlled trial (BABY HUG). Lancet 2011;377(9778):1663–72. https://doi.org/10.1016/S0140-6736(11)60355-3
- Adegoke SA, Adeodu OO, Adekile AD. Sickle cell disease clinical phenotypes in children from South-Western, Nigeria. Niger J Clin Pract. 2015;18(1):95-101. PMid:25511352
- Serjeant GR. Fetal hemoglobin in homozygous sickle cell disease Clin Haematol 1975;4:109-22. PMid:1102178
- Oyedeji GA. Socioeconomic and cultural background of hospitalised children in Ilesa. Niger J Paediatr. 1985;12:111-7.
- Ballas SK, Lieff S, Benjamin LJ, Dampier CD, Heeney MM, Hoppe C, et al. Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol 2010;85:6-13. PMid:19902523 PMCid:PMC5046828
- Adegoke SA, Kuti BP. Evaluation of clinical severity of sickle cell anemia in Nigerian children. J Applied Hematol. 2013;4:58-64.
- Mpalampa L, Ndugwa CM, Ddungu H, Idro R. Foetal haemoglobin and disease severity in sickle cell anaemia patients in Kampala, Uganda. BMC Blood disorders. 2012;12:11. https://doi.org/10.1186/1471-2326-12-11 PMid:22958547 PMCid:PMC3520739
- Norman NH, Nie, Hull CH. Statistical package for social sciences for Windows. 17.0 ed. Chicago: SPSS Incoporation; 2008.
- Akinsheye I, Alsultan A, Solovieff N, Ngo D, Baldwin CT, Sebastian P, et al. Fetal hemoglobin in sickle cell anemia. Blood. 2011;118(1):19-27. https://doi.org/10.1182/blood-2011-03-325258 PMid:21490337 PMCid:PMC3139383
- Brown B, Jacob N, Lagunju I, Jarrett O. Morbidity and mortality pattern in hospitalized children with sickle cell disorders at the University College Hospital, Ibadan, Nigeria. Niger J Paed. 2013;40(1):34-9.
- Brozovic M, Davies S, Alison I, Brownell A. Acute admissions of patients with sickle cell disease who live in Britain. Br Med J. 1987;294:1206-8. https://doi.org/10.1136/bmj.294.6581.1206
- Wasil J. Epidemiology of sickle cell disease in Saudi Arabia. Ann Saudi Med. 2011 31:289-93. https://doi.org/10.4103/0256-4947.81540 PMid:21623060 PMCid:PMC3119971
- Adewoyin AS. Management of Sickle Cell Disease: a review for physician education in Nigeria (Sub-Saharan Africa). Anemia. 2015;2015:e791498.
- Isah IZ, Udomah FP, Erhabor O, Aghedo F, Uko EK, Okwesili AN, et al. Foetal haemoglobin levels in sickle cell disease patients in Sokoto, Nigeria. Br J Med Health Sci. 2013;1:36-47.
- Tshilolo L, Summa V, Gregorj C, Kinsiama C, Bazeboso JA, Avvisati G, et al. Foetal haemoglobin, erythrocytes containing foetal haemoglobin, and hematological features in Congolese patients with sickle cell anaemia. Anemia. 2012;2012:e105349
- Olaniyi JA, Arinola OG, Odetunde AB. Foetal haemoglobin (HbF) status in adult sickle cell anaemia patients in Ibadan, Nigeria. Ann Ibadan Postgrad Med. 2010;8:30-3. PMid:25161472 PMCid:PMC4138770
- Durosimi MA, Salawu L, Ova YAA, Lawal OO, Fadiran OA. Haematological parameters in sickle cell anaemia patients with and without splenomegaly. Niger Postgrad Med J. 2005;12(4):271-4.
- Uko E, Useh M, Gwanmesia F. Frequency of foetal haemoglobin and haemoglobin values in various haemoglobin genotypes in Calabar, Nigeria. East Afr Med J. 1997;74(12):809-11. PMid:9557428
- Omoti CE. The value of foetal haemoglobin level in the management of Nigerian sickle cell anaemia patients. Niger Postgrad Med J. 2005;12(3):149-54. PMid:16160713
- Rao SS, Goyal JP, Raghunath SV, Shah VB. Hematological profile of sickle cell disease from South Gujarat, India. Hematol Reports. 2012;4:e8. https://doi.org/10.4081/hr.2012.e8 PMid:22826798 PMCid:PMC3401137
- Nagel RL, Fabry ME, Pagnier J, Zohoun I, Wajcman H, Baudin V, et al. Hematologically and genetically distinct forms of sickle cell anemia in Africa. N Engl J Med 1985 321:880. https://doi.org/10.1056/NEJM198504043121403 PMid:2579336
- Aimola IA, Inuwa HM, Nok AJ, Mamman AI. Induction of foetal haemoglobin synthesis in erythroid progenitor stem cells: mediated by water-soluble components of Terminalia catappa. Cell Biochem Funct. 2014;32(4):361-7. https://doi.org/10.1002/cbf.3024 PMid:24470326
- Falusi AG, Esan GJ. Foetal haemoglobin levels in sickle cell anaemia in Nigerians. Afr J Med Sci. 1989;18:145-9.
- Mouele R. Haemoglobin F (HbF) levels in sickle-cell anaemia patients homozygous for the Bantu haplotype. European Journal of Haematology. 1999;63:136–7. https://doi.org/10.1111/j.1600-0609.1999.tb01128.x PMid:10480294
- Alsultan A, Solovieff N, Aleem A, AlGahtani FH, Al-Shehri A, Osman ME, et al. Fetal hemoglobin in sickle cell anemia: Saudi patients from the Southwestern province have similar HBB haplotypes but higher HbF levels than African Americans. Am J Hematol. 2011;86(7):612-4. https://doi.org/10.1002/ajh.22032 PMid:21630302
- Dover GJ, Smith KD, Chang YC, Purvis S, Mays A, Meyers DA, et al. Fetal Hemoglobin Levels in Sickle Cell Disease and Normal Individuals Are Partially Controlled by an X-Linked Gene Located at Xp22.2. Blood 1993;80(3):816-24.
- Adekile A, Al-Kandari M, Haider M, Rajaa M, D'Souza M, Sukumaran J. Hemoglobin F concentration as a function of age in Kuwaiti sickle cell disease patients. Med Princ Pract. 2007;16(4):286-90. https://doi.org/10.1159/000102151 PMid:17541294
- Trompeter S, Roberts I. Haemoglobin F modulation in childhood sickle cell disease. Br J Haematol. 2008;144:308–16. https://doi.org/10.1111/j.1365-2141.2008.07482.x PMid:19036119